Related references
Note: Only part of the references are listed.A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults
Neil French et al.
MALAWI MEDICAL JOURNAL (2016)
Novel Protein-Based Pneumococcal Vaccines Administered with the Th1-Promoting Adjuvant IC31 Induce Protective Immunity against Pneumococcal Disease in Neonatal Mice
Thorunn Asta Olafsdottir et al.
INFECTION AND IMMUNITY (2012)
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands
David R. Strutton et al.
JOURNAL OF INFECTION (2012)
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan
Li-Min Huang et al.
VACCINE (2012)
Immunization with the RrgB321 fusion protein protects mice against both high and low pilus-expressing Streptococcus pneumoniae populations
Monica Moschioni et al.
VACCINE (2012)
Study of nasopharyngeal carriage of Streptococcus pneumoniae and its antibiotics resistance in healthy children aged less than 2 years in the Marrakech region (Morocco)
M. Bouskraoui et al.
ARCHIVES DE PEDIATRIE (2011)
Safety and Immunogenicity of Coadministering a Combined Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine with 7-Valent Pneumococcal Conjugate Vaccine and Measles, Mumps, and Rubella Vaccine at 12 Months of Age
Elizabeth Miller et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
Geographic Variation in Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccine Introduction in the United States
Jennifer B. Rosen et al.
CLINICAL INFECTIOUS DISEASES (2011)
Review on the immunogenicity and safety of PCV-13 in infants and toddlers
Marta C. Nunes et al.
EXPERT REVIEW OF VACCINES (2011)
Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study
Elizabeth Miller et al.
LANCET INFECTIOUS DISEASES (2011)
Carried Pneumococci in Massachusetts Children The Contribution of Clonal Expansion and Serotype Switching
William P. Hanage et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2011)
Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine
Robert Frenck et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2011)
Risk of Red Queen dynamics in pneumococcal vaccine strategy
Johanna M. C. Jefferies et al.
TRENDS IN MICROBIOLOGY (2011)
Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy
Sara Boccalini et al.
VACCINE (2011)
Cost-effectiveness analysis of the 10-and 13-valent pneumococcal conjugate vaccines in Argentina
Analia Uruena et al.
VACCINE (2011)
The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America
Norberto Giglio et al.
VACCINE (2011)
Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US
K. M. Shea et al.
VACCINE (2011)
Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine
Francisco Gimenez-Sanchez et al.
VACCINE (2011)
Economic evaluation of second generation pneumococcal conjugate vaccines in Norway
Bjarne Robberstad et al.
VACCINE (2011)
Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine
Janusz Gadzinowski et al.
VACCINE (2011)
Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children
Anna S. Tocheva et al.
VACCINE (2011)
Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose
K. P. Klugman et al.
VACCINE (2011)
Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model
Julie M. Skinner et al.
VACCINE (2011)
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A
David Cooper et al.
VACCINE (2011)
Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1 x, 2x, or 4x) in healthy subjects aged 70 years or older
H. Lode et al.
VACCINE (2011)
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants
E. Grimprel et al.
VACCINE (2011)
A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years
T. F. Schwarz et al.
VACCINE (2011)
Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
Elizabeth Miller et al.
VACCINE (2011)
Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study
Stefan Flasche et al.
PLOS MEDICINE (2011)
Economic evaluation of pneumococcal conjugate vaccination in The Gambia
Sun-Young Kim et al.
BMC INFECTIOUS DISEASES (2010)
Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers
Susanna Esposito et al.
CLINICAL AND VACCINE IMMUNOLOGY (2010)
Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines
Daniel J. Isaacman et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2010)
Safety and Antibody Response, Including Antibody Persistence for 5 Years, after Primary Vaccination or Revaccination with Pneumococcal Polysaccharide Vaccine in Middle-Aged and Older Adults
Daniel M. Musher et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine
Tamara Pilishvili et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
PavB is a surface-exposed adhesin of Streptococcus pneumoniae contributing to nasopharyngeal colonization and airways infections
Inga Jensch et al.
MOLECULAR MICROBIOLOGY (2010)
A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults.
Neil French et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age A Double-blind Randomized Active-controlled Trial
Matthew D. Snape et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2010)
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers
Sylvia H. Yeh et al.
PEDIATRICS (2010)
Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries
Sandra E. Talbird et al.
VACCINE (2010)
Clinical and economic burden of pneumococcal disease in older US adults
Derek Weycker et al.
VACCINE (2010)
Control of Streptococcus pneumoniae serotype 5 epidemic of severe pneumonia among young army recruits by mass antibiotic treatment and vaccination
Ran D. Balicer et al.
VACCINE (2010)
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States
Jaime L. Rubin et al.
VACCINE (2010)
GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis
Ying-Jie Lu et al.
VACCINE (2010)
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany
Dorothee M. Kieninger et al.
VACCINE (2010)
Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project
Hope L. Johnson et al.
PLOS MEDICINE (2010)
Increase in Serotype 6C Pneumococcal Carriage, United Kingdom
Anna S. Tocheva et al.
EMERGING INFECTIOUS DISEASES (2010)
Superior Immune Response to Protein-Conjugate versus Free Pneumococcal Polysaccharide Vaccine in Chronic Obstructive Pulmonary Disease
Mark T. Dransfield et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae
Dylan R. Pillai et al.
BMC GENOMICS (2009)
Efficacy of pneumococcal vaccination in adults: a meta-analysis
Anke Huss et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection
J. Cao et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
The Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine in Adults Aged 50-80 Years
David Goldblatt et al.
CLINICAL INFECTIOUS DISEASES (2009)
Modeling the Impact of a New Vaccine on Pneumococcal and Nontypable Haemophilus influenzae Diseases: A New Simulation Model
Philippe De Wals et al.
CLINICAL THERAPEUTICS (2009)
Increase in the Prevalence of the Newly Discovered Pneumococcal Serotype 6C in the Nasopharynx after Introduction of Pneumococcal Conjugate Vaccine
Moon H. Nahm et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates
Katherine L. O'Brien et al.
LANCET (2009)
Microbial Interactions in the Respiratory Tract
Timothy F. Murphy et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2009)
Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada
I. Feavers et al.
VACCINE (2009)
Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits
Angelique G. S. C. Jansen et al.
VACCINE (2009)
Emergence of Streptococcus pneumoniae Serotypes 19A, 6C, and 22F and Serogroup 15 in Cleveland, Ohio, in Relation to Introduction of the Protein-Conjugated Pneumococcal Vaccine
Michael R. Jacobs et al.
CLINICAL INFECTIOUS DISEASES (2008)
Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection
Lisa A. Jackson et al.
CLINICAL INFECTIOUS DISEASES (2008)
Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults:: Conjugate vaccine elicits improved antibacterial immune responses and immunological memory
Andres de Roux et al.
CLINICAL INFECTIOUS DISEASES (2008)
Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia
Daniel M. Musher et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia
M. Saaka et al.
VACCINE (2008)
Outbreak of Streptococcus pneumoniae serotype 1 pneumonia in a United Kingdom school
Atul Gupta et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae -: and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization-in HIV-infected and HIV-uninfected children
Shabir A. Madhi et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the united states during the era of widespread PCV7 vaccination, 1998-2004
Lauri A. Hicks et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults
Daniel A. Scott et al.
VACCINE (2007)
Immunogenicity of varying dosages of 7-valent pneurnococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Lisa A. Jackson et al.
VACCINE (2007)
Longitudinal study on pneumococcal carriage during the first year of life in Bangladesh
Simo M. Granat et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2007)
The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease
William P. Hausdorff
VACCINE (2007)
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study
Cynthia G. Whitney et al.
LANCET (2006)
Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers
D Goldblatt et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2006)
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae:: a randomised double-blind efficacy study
R Prymula et al.
LANCET (2006)
The current burden of pneumococcal disease in England and Wales
A Melegaro et al.
JOURNAL OF INFECTION (2006)
Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004
SS Huang et al.
PEDIATRICS (2005)
Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine
SL Kaplan et al.
PEDIATRICS (2004)
Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children
AB Brueggemann et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection
KP Klugman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants
L Jódar et al.
VACCINE (2003)
Effectiveness of pneumococcal polysaccharide vaccine in older adults
LA Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Global burden of acute respiratory infections in children: Implications for interventions
K Mulholland
PEDIATRIC PULMONOLOGY (2003)
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia
SB Black et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2002)
Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I
WP Hausdorff et al.
CLINICAL INFECTIOUS DISEASES (2000)
Share Paper
